OMX Copenhagen 20
1 517,81
|
-102,00
|
-6,30%
|
Analysen zu OMX Copenhagen 20-Werten
26.06.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
26.06.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
26.06.23 | Novo Nordisk Sell | UBS AG | |
20.06.23 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
19.06.23 | Novo Nordisk Sell | UBS AG | |
15.06.23 | A.P. Moeller - Maersk A-S Overweight | JP Morgan Chase & Co. | |
12.06.23 | Novo Nordisk Sell | UBS AG | |
08.06.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
26.05.23 | Novo Nordisk Sell | UBS AG | |
23.05.23 | Novo Nordisk Overweight | Barclays Capital | |
23.05.23 | Novo Nordisk Buy | Deutsche Bank AG | |
22.05.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
22.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
08.05.23 | A.P. Moeller - Maersk A-S Neutral | UBS AG | |
05.05.23 | Novo Nordisk Buy | Deutsche Bank AG | |
05.05.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
05.05.23 | A.P. Moeller - Maersk A-S Overweight | JP Morgan Chase & Co. | |
05.05.23 | Novo Nordisk Outperform | Credit Suisse Group | |
04.05.23 | Novo Nordisk Sell | UBS AG | |
04.05.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
28.04.23 | Novo Nordisk Sell | UBS AG | |
27.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
20.04.23 | Novo Nordisk Overweight | Barclays Capital | |
18.04.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
18.04.23 | Novo Nordisk Buy | Deutsche Bank AG | |
14.04.23 | Novo Nordisk Sell | UBS AG | |
14.04.23 | Novo Nordisk Overweight | Barclays Capital | |
13.04.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
13.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
13.04.23 | Novo Nordisk Outperform | Credit Suisse Group | |
12.04.23 | Novo Nordisk Overweight | Barclays Capital | |
11.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. |